Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Quinazoline derivative salt form crystal form, preparation method and application

A technology of quinazoline and derivatives, applied in the preparation of carboxylate, sulfonate, preparation of organic compounds, etc., can solve problems such as inability to effectively suppress, unfavorable use, etc., and achieves reduction of tablet intake burden and resistance to drug resistance. drug, good pharmacokinetic effect

Active Publication Date: 2021-06-04
WEISHANG (SHANGHAI) BIO PHARMA CO LTD
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] The problem to be solved by the present invention is that the existing EGFR inhibitors cannot effectively inhibit the EGFR activation mutation EGFRVIII and effectively pass through the blood-brain barrier to reach an effective blood concentration in the brain, and the quinazoline derivatives (R )-6-[(3,3-difluoro-1-methylpiperidin-4-yl)oxy]-nitrogen-(3-ethynyl-2-fluorophenyl)-7-methoxyquinazole The properties of the free base of line-4-amine (I) are unfavorable for the problem of using in pharmaceutical processing and pharmaceutical compositions, providing a kind of quinazoline derivative salt form crystal that is more conducive to pharmaceutical processing and pharmaceutical compositions Types, preparation methods and applications, providing more qualitative and quantitative information for the efficacy and safety research of solid drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Quinazoline derivative salt form crystal form, preparation method and application
  • Quinazoline derivative salt form crystal form, preparation method and application
  • Quinazoline derivative salt form crystal form, preparation method and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0352] The preparation of embodiment 1. quinazoline derivatives (I)

[0353] 1.1 Synthesis of intermediates 5-fluoro-4-methoxy-2-nitrobenzonitrile A6 and 1-bromo-5-fluoro-4-(deuteromethoxy)-2-nitrobenzene C1

[0354] The synthetic route is as follows:

[0355]

[0356] Step 1: To a solution of A1 (2.0 g, 10.5 mmol) and triethylamine (1.3 g, 12.6 mmol) in dichloromethane (10 mL) was added dropwise ethyl chloroformate in dichloromethane (3 mL) at 0 °C Ester (1.4 g, 12.6 mmol) solution. The reaction mixture was stirred at 0 °C for 1 h and allowed to reach room temperature. The reaction mixture was then washed twice with water. The organic layer was dried over magnesium sulfate and evaporated in vacuo to afford product A2 (2.7 g, 100% yield) as a colorless oil.

[0357] Step 2: To a solution of A2 (2.7 g, 10.3 mmol) in concentrated sulfuric acid (4.6 mL) was added dropwise fuming nitric acid (0.73 mL, 15.5 mmol) at 10°C. After 1 hour, the reaction mixture was poured into i...

Embodiment 2

[0384] Embodiment 2. Preparation of the hydrochloride crystal form A of quinazoline derivatives (I) of the present invention

[0385] Weigh about 20 mg of quinazoline derivatives shown in formula (I) (i.e., (R)-6-[(3,3-difluoro-1-methylpiperidin-4-yl) oxy]- Nitrogen-(3-ethynyl-2-fluorophenyl)-7-methoxyquinazolin-4-amine (I)) sample in 1.5 milliliter vials, add 0.6 milliliters of methyl alcohol and 46 microliters of hydrochloric acid (1mol / L), after stirring at room temperature for about two days, centrifuge to separate the lower layer of wet sample solid. According to XRPD detection, the solid is hydrochloride crystal form A.

Embodiment 3

[0386] Embodiment 3. Preparation of the hydrochloride crystal form B of quinazoline derivatives (I) of the present invention

[0387] Take by weighing the quinazoline derivative sample shown in formula (I) of about 160 milligrams, add 5 milliliters of tetrahydrofuran / water (19 / 1, v / v), and in this suspension, add the hydrochloric acid of 0.37 milliliters (1mol / L ), stirred at room temperature for about two days, and centrifuged to separate the lower layer of wet sample solid. According to XRPD detection, the solid is hydrochloride crystal form B.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a quinazoline derivative salt form crystal form and its preparation method and application; specifically, the hydrochloride salt form A, B, C, D, F of the quinazoline derivative represented by formula (I) , H, I, Sulfate Form A, Maleate Form A, Succinate Form A, Adipate Form A, Glycolate Form A, Malate Form A, Fuma Acid salt form A, besylate form A, B, C, benzoate form A, hippurate form A and oxalate form A. The salt crystal form provided by the present invention has good stability, can be used in medicines for the treatment of non-small cell lung cancer brain metastasis, meningeal metastasis, primary brain cancer or glioma, etc., and has good bioavailability It is of great significance to further study the curative effect of this kind of solid medicine.

Description

technical field [0001] The present invention relates to a quinazoline derivative salt form and its crystal form; specifically to (R)-6-[(3,3-difluoro-1-methylpiperidin-4-yl)oxyl]-nitrogen -(3-ethynyl-2-fluorophenyl)-7-methoxyquinazolin-4-amine (I) hydrochloride crystal form A, B, C, D, F, H, I, sulfuric acid Salt Form A, Maleate Form A, Succinate Form A, Adipate Form A, Glycolate Form A, Malate Form A, Fumarate Form A, Besylate crystal forms A, B, C, benzoate crystal form A, hippurate crystal form A and oxalate crystal form A and their preparation methods and applications. Background technique [0002] Biological signal transduction refers to the sending of stimulating or inhibiting signals into cells, and through a series of signal transmissions, biological responses occur in cells. Many signaling pathways and their biological responses have been studied extensively. Distinct defects in signaling pathways have been found to be responsible for many diseases, including var...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07D401/12C07C51/41C07C57/15C07C55/10C07C57/145C07C59/06C07C55/07C07C59/245C07C63/08C07C303/32C07C309/29C07C231/12C07C233/83A61K31/517A61P35/00
CPCA61P35/00C07B2200/13C07D401/12
Inventor 钟卫张金强
Owner WEISHANG (SHANGHAI) BIO PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com